- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04070612
National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia. (BIOCEREVANCE)
National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
These autoimmune haematological diseases are rare diseases affecting the child, often very young, and serious and potentially life-threatening. International literature data are scarce, and include individual cases or small series.
They do not allow to determine an optimal therapeutic strategy in case of escape from the first-line treatments. Existing treatments (long-term corticosteroid therapy, immunoglobulins, splenectomy, immunosuppressants, chemotherapies, and more recently anti-CD20 antibodies) are inconsistently effective, and often associated with serious side effects.
The seriousness of these diseases, the therapeutic difficulties, and the absence of a targeted research project in France, led to the implementation of this study.
This study aims to study prospectively the clinical and paraclinical evolution and prognostic factors of autoimmune haemolytic anemias, Evans syndromes and chronic immunological thrombocytopenic purpura of children in France.
Studietype
Inschrijving (Werkelijk)
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age strictly below 18 years of age at initial diagnosis
- Affiliate child or beneficiary of a social security scheme
- Child residing in metropolitan France
- Diagnosis of autoimmune haemolytic anemias, Evans syndrome and / or chronic Immune thrombocytopenic purpura
- Free, informed, written and signed consent
Exclusion Criteria:
- Diagnosis of constitutional haemolytic anemia
- Diagnosis of platelet constitutional disease
Studie plan
Hoe is de studie opgezet?
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
---|---|
children with autoimmune haemolytic anemia
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Children with Evans syndrome
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Children with Immune thrombocytopenic purpura
A blood sample of 2 times 2 to 5 ml additional maximum
|
A blood sample of 2 times 2 to 5 ml additional maximum
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Complete sustainable remission (yes/no) for children with autoimmune haemolytic anemias
Tijdsspanne: At the screening
|
Absence of clinical signs of anemia (grade 0) And Hemoglobin > 11 g / dl And reticulocytes <120,000 / mm3 And haptoglobin> 10 mg / dl And bilirubin <10 mg / l or 17 μmol / l And no specific treatment for at least 12 months
|
At the screening
|
complete remission (yes/no) for children with autoimmune haemolytic anemias
Tijdsspanne: At the screening
|
Absence of clinical signs of anemia (grade 0) And Hemoglobin> 11 g / dl And reticulocytes <120,000 / mm3 Regardless of the level of haptoglobin or bilirubin And specific treatment in progress or interrupted for less than 12 months
|
At the screening
|
partial remission (yes/no) for children with autoimmune haemolytic anemias
Tijdsspanne: At the screening
|
Clinical Signs of Anemia (Grade 1 or 2) Or Hemoglobin from 7 to 11 g / dl Or reticulocytes> 120,000 / mm3 Regardless of the level of haptoglobin or bilirubin
|
At the screening
|
no response (yes/no) for children with autoimmune haemolytic anemias
Tijdsspanne: At the screening
|
Clinical Signs of Severe Anemia (Grade 3 or More) Or Hemoglobin <7 g / dl
|
At the screening
|
deceased patient (yes/no) for children with autoimmune haemolytic anemias
Tijdsspanne: At the screening
|
Death yes/no
|
At the screening
|
Complete sustainable remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tijdsspanne: At the screening
|
Absence of clinical signs of haemorrhage (grade 0) And platelets> 100,000 / mm3 And no specific treatment for at least 12 months
|
At the screening
|
complete remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tijdsspanne: At the screening
|
Absence of clinical signs of haemorrhage (grade 0) And platelets> 100,000 / mm3 And specific treatment in progress or interrupted for less than 12 months
|
At the screening
|
partial remission (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tijdsspanne: At the screening
|
Clinical Signs of Hemorrhage (Grade 1 or 2) Or platelets between 30,000 and 100,000 / mm3
|
At the screening
|
no response (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tijdsspanne: At the screening
|
Clinical Signs of Severe Hemorrhage (Grade 3 or Greater) Or Platelets <30,000 / mm3
|
At the screening
|
deceased patient (yes/no) for children with chronic immunologic thrombocytopenic purpura
Tijdsspanne: At the screening
|
Death yes/no
|
At the screening
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Yves PEREL, Pr, Bordeaux University Hsopital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Ziekten van het immuunsysteem
- Auto-immuunziekten
- Hematologische ziekten
- Bloeding
- Hemorragische aandoeningen
- Bloedarmoede
- Bloedstollingsstoornissen
- Manifestaties van de huid
- Trombocytopenie
- Bloedplaatjesstoornissen
- Trombotische microangiopathieën
- Purpura
- Purpura, trombocytopenisch
- Purpura, trombocytopenisch, idiopathisch
- Bloedarmoede, hemolytisch
- Bloedarmoede, hemolytisch, auto-immuun
Andere studie-ID-nummers
- CHUBX 2005/18
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Blood sample
-
Hillel Yaffe Medical CenterOnbekend